ArticleExperimental and therapeutic medicine2026
Pan-cancer analysis of the oncogenic role of SRY-related high-mobility group box protein B5 in human tumors.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SRY-related high-mobility group protein B5 (SOX5) functions as an oncogene in diverse human malignancies, contributing to tumor progression, metastasis and therapy resistance across various cancer types. In light of this, a pan-cancer analysis was performed in the present study to investigate the oncogenic function of SOX5 in various human malignancies. SOX5 mRNA expression levels were compared between normal and malignant tissues using The Cancer Genome Atlas database and diagnostic effectiveness was evaluated using receiver operating characteristic curve analysis. Kaplan-Meier survival analysis was performed to investigate the association between SOX5 expression and overall survival, disease-specific survival, disease-free interval and progression-free interval. The influence of SOX5 on immune infiltration and immunological scores in the tumor microenvironment was assessed utilizing Estimation of Stromal and Immune Cells in Malignant Tumor Tissues Using Expression Data, Cell-Type Identification by Estimating Relative Subsets of RNA Transcripts and single-sample Gene Set Enrichment Analysis methodologies, in conjunction with its relationship to drug sensitivity and genetic modifications. SOX5 exhibited tissue-specific dysregulation, being markedly downregulated in carcinomas such as lung adenocarcinoma (LUAD), lung squamous cell carcinoma and breast cancer, while increased in testicular germ cell tumor and non-small cell lung cancer (NSCLC) cell lines. It demonstrated notable diagnostic potential, with good performance in LUAD (area under the curve=0.916). The prognostic relevance of SOX5 was contingent upon context as lower expression conferred protection in specific malignancies; however, it was associated with worse outcomes in others, such as low-grade glioma and pancreatic adenocarcinoma. Increased SOX5 expression was associated with an immunosuppressive milieu marked by a rise in regulatory T cells, a decline in cytotoxic T cells and the activation of immunological checkpoints including programmed death-ligand 1 and cytotoxic T lymphocyte associated protein 4. Moreover, SOX5 was associated with genomic instability, susceptibility to medicines such as azacitidine and distinct mutation patterns. SOX5 suppression in NSCLC cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.